Introduction
============

Stroke is the second commonest cause of death and commonest cause of dependence in adults worldwide. A fifth of all strokes, a quarter of all ischaemic strokes, are lacunar in type and part of the spectrum of cerebral small vessel disease (SVD) [@b1]. SVD also causes cognitive and physical disabilities [@b2], doubles the risk of dementia and trebles the risk of stroke [@b3].

Cerebral SVD affects the penetrating arterioles supplying the cerebral white and deep grey matter [@b1]. Human pathology, often late stage and thus hard to unravel [@b4], includes arteriolar vessel wall thickening, perivascular inflammation, arteriolar wall disintegration [@b5] and perivascular damage particularly oedema and demyelination [@b6] commonly considered to be a consequence of ischaemia [@b4]. Hypertension is the main known vascular risk factor for SVD [@b7]. However, some individuals with pathological evidence of SVD lacked evidence of having been hypertensive in life [@b8], and trials of antihypertensive drugs have had mixed success in preventing SVD progression 9--11.

We considered that examination of different potential SVD mechanisms in experimental models might provide insight into pathogenesis of human SVD. Although several models exist we focused on the spontaneously hypertensive stroke-prone rat (SHRSP), which is genetically stable and known to mimic spontaneously the human microvascular and brain tissue changes [@b12],[@b13]. The SHRSP was bred from the Wistar-Kyoto rat (WKY) via the spontaneously hypertensive rat (SHR) [@b14]. It starts to develop hypertension after 6 weeks of age and strokes begin to occur from around 20 weeks [@b12]. It develops lipohyalinosis and fibrinoid necrosis, small deep infarcts, haemorrhages, white matter abnormalities and perivascular space enlargement spontaneously that resemble the pathological changes associated with human SVD [@b12],[@b14]. Although traditionally attributed to hypertension, we found differences in protein expression in SHRSPs (*vs.* age-matched WKY controls) at only 5 weeks of age, that is before blood pressure rises, which persist at 16 and 21 weeks of age [@b15]. These endothelial, glial, astrocyte, microglial and matrix protein abnormalities provide a potential mechanism to explain the SHRSP\'s vulnerability to cerebral microvascular and parenchymal damage [@b15].

Components of human SVD are highly heritable, but so far human genome-wide association studies (GWAS) have identified few genes associated with white matter hyperintensities (mostly of unknown function) and none so far for lacunar stroke 16--18. The genetic factors that render the SHRSP stroke-prone are also poorly understood. Known differences between SHRSP and WKY include STR-2 quantitative trait loci on chromosome 5 colocalized with genes encoding atrial and brain natriuretic peptides 19--21, a single-nucleotide polymorphism (SNP) on chromosome 2 (R202H) associated with reduced glutathione S-transferase expression [@b22], and, from a recent GWAS, a number of candidate genes for hypertension in spontaneously hypertensive rat substrains [@b23], but which are not known to affect stroke directly [@b24].

We hypothesized that the predisposition of SHRSP to cerebral microvascular and brain tissue pathology is multifactorial, involves several pathways, with no single genetic defect accounting for all the structural and pathological changes. We assessed mRNA expression in the brain by microarray, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and pathway analysis in SHRSP and WKY fed a normal diet at 5, 16 and 21 weeks in the two brain regions (frontal and mid-coronal), which are known to express maximal pathology [@b15].

Materials and methods
=====================

Animals and tissue
------------------

All animals were kept and experiments conducted according to UK regulations for live animal research in licensed laboratories (licence No. 60/3618) and conducted according to the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines (<http://www.nc3rs.org/ARRIVE>). We also report our results according to the Minimum Information About a Microarray Experiment (MIAME) 2.0 criteria (<http://www.mged.org/Workgroups/MIAME/miame_2.0.html>).

SHRSP rats were considered the most appropriate model of human SVD available based on a detailed systematic review undertaken within the lab [@b12]. It is accepted that no animal model will ever truly and completely represent a human disease, but the data generated from a carefully chosen model can inform and focus subsequent translational research.

We used four male SHRSP~Gla~ (designated SHRSP) and WKY~Gla~ (designated WKY) animals in each of three age groups (5, 16 and 21 weeks, total animals *n* = 24) from the Glasgow colony, the same animals having been used to generate earlier immunohistochemistry data, thereby providing a direct intra-animal immunohistochemistry-mRNA comparison. Five-week-old animals were considered prehypertensive as SHRSP have consistently not shown any difference in blood pressure (BP) until after 6 weeks in SHRSP from this colony in prior work compared with control rats [@b25], with BP measurements always taken from conscious animals. We considered 15-week-old rats to represent established hypertension, and 21 weeks as an age at which strokes were commonly seen to start. We kept all animals in identical conditions and fed both strains on standard rat chow *ad libitum* (Rat and Mouse No. 1 Maintenance Diet, Special Diet Services). We used tail cuff plethysmography to take measurements of systolic blood pressure on a weekly basis in older rats. We sacrificed animals by overdose of isofluorane anaesthetic plus exsanguination. We preserved one cerebral hemisphere in formalin and the other hemisphere in liquid nitrogen for mRNA analysis as previously described [@b15]. For mRNA analysis, we immersed each frozen hemisphere in ×10 volume of RNA-later ice solution and incubated for 24 h at −20°C so that the following day 2 mm coronal slices from a frontal and a mid-coronal region could be taken using a Zivic® rat slicer matrix (Zivic Instruments, Pittsburgh, PA, USA) which captured the frontal cortex, thalamus, internal capsule and basal ganglia. These represent the areas most susceptible to cerebral and vascular pathology in the SHRSP [@b12].

RNA extraction
--------------

We placed each coronal slice in approximately 1.5 ml (×10 volume) of lysis buffer (Qiazol) and homogenized the tissue using a POLYTRON® homogenizer (Capitol Scientific Inc., Austin, TX, USA). We extracted RNA using a Qiagen RNAeasy lipid tissue minikit (Qiagen Ltd., Manchester, UK). We eluted the resulting RNA with nuclease free water (2 × 50 μl). We treated half the elute with turbo DNase to remove any remaining genomic DNA and assessed the quality of the resulting RNA on a Nanodrop 1000 and Agilent® bioanalyser 2100 (Agilent, Santa Clara, CA, USA).

RNA amplification and purification
----------------------------------

We performed transcriptions from RNA to cRNA using an Ambion® Illumina® Total Prep RNA amplification kit (Applied Biosystems, Foster City, CA, USA). We generated first-strand cDNA with a first-strand master mix containing an oligo (dT) tagged with a phage T7 promotor and second-strand cDNA with a master mix containing DNA polymerase. We added the *in vitro* master mix solution to the elute according to kit instructions to amplify and label the cDNA with biotin UTP. We obtained a final cRNA elute of ∼200 μl and checked cRNA quality on the Agilent® bioanalyser.

Microarray mRNA expression analysis
-----------------------------------

We added 5 μl of cRNA (∼750 ng) to 10 μl of hybridization buffer and loaded the resulting 15 μl onto a RatRef12 microarray chip (Illumina, San Diego, CA, USA), containing 22 519 gene and probe sets. We incubated chips at 58°C overnight, washed them with E1BC solution and stained them in a solution of E1 buffer plus 1:1000 dilution of streptavidin-Cy3. We scanned chips on an Illumina® Bead Reader (Illumina, San Diego, CA, USA) and recorded the intensity of fluorescent signal emitted. Samples with a signal intensity of \>600 passed the bead array reader\'s quality control. We randomized samples throughout the entire microarray protocol and all samples were hybridized to the chips and scanned at the same time.

qRT-PCR
-------

Using the same DNase-treated RNA from the microarray experiment as the template for the synthesis of cDNA, we performed qRT-PCR reactions using Applied Biosystems Taqman® Gene Expression Assay (Applied Biosystems, Foster City, CA, USA) to quantitatively confirm differential expression measured in the microarray experiment. Briefly, we reverse transcribed 20 μl reactions on a 96-well plate containing approximately 1 μg of RNA using the Taqman® reverse transcription master mix (Applied Biosystems, Foster City, CA, USA) including OligodT primers and Multiscribe™ reverse transcriptase enzyme. We performed qRT-PCR on the cDNA by creating a reaction mix in the same Eppendorf containing Taqman® universal master mix (Applied Biosystems, Foster City, CA, USA) plus a probe for a housekeeping (control) gene \[Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (VIC® labelled)\] and the Taqman® probe corresponding to our gene of interest (FAM® labelled). We ran samples on a 384-well plate on a 7900HT Sequence detector (Applied Biosystems, Foster City, CA, USA).

Standard PCR
------------

We designed forward and reverse primers corresponding to the portion of the GUCY1a3 gene sequence covered by the Illumina® microarray probe. To test for insertions or deletions within the sequence between strains we ran end-point PCR using these primers, on DNA taken from the livers of additional SHRSP (*n* = 4) and WKY (*n* = 3). We used 'Kod Hot Start' DNA polymerase (Novagen, Merck, Darmstadt, Germany) and performed PCR reactions using the designated kit and to manufacturer\'s instructions. Extension times depended on the length of sequence being created. We performed all PCR reactions on a MJ Research Peltier Thermal Cycler (<http://www.mj-research.com>) using 96-well plates. We analysed results using agarose gel electrophoresis. We visualized gels on a Bio-Rad Fluor-S Multimager and assessed the size of PCR products using Promega 100 bp or 1 kb DNA ladders (Promega, Madison, WI, USA).

DNA sequencing
--------------

We used Applied Biosystems BigDye Terminator n3.1 Cycle Sequencing kits (Applied Biosystems, Foster City, CA, USA) for all sequencing reactions and performed reactions in 96-well plates (SHRSP *n* = 2, WKY *n* = 3 taken from the samples used for standard PCR). We loaded a reaction solution of sequencing buffer, ready reaction, primer, purified PCR product and water into each well. To sequence, we used a temperature cycling programme of 96°C for 45 s, 50°C for 25 s and 60°C for 4 min, repeated 25 times. We performed sequencing capillary electrophoresis on a 48-capillary Applied Biosystems 3730 Genetic Analyser with 36 cm capillaries filled with POP-7 polymer (Applied Biosystems, Foster City, CA, USA) and warmed to 60°C. We separated sequencing products by size using electrophoresis set to 8500 V for 50 min.

Data analysis
-------------

### Microarray data

We analysed data using Rank Products (RP) analysis, a nonparametric statistical technique [@b26] complete with Bejamini-Hochberg false discovery rate (FDR) adjustment for multiple testing. FDR \< 0.05 was considered significant. We did not set a minimum individual fold change for significance as we were interested in pathway interactions. We first generated Venn diagrams to visualize the results by age and brain section, then uploaded focus genes onto the Ingenuity Pathway Analysis® (IPA) (Ingenuity Systems, <http://www.ingenuity.com>) and analysed data using both a prespecified candidate gene approach (looking for changes in genes and pathways thought to be relevant from previous work by ourselves and others) and a genome-wide approach (to generate new hypotheses). Significance of pathways was assessed using one-sided Fisher\'s exact tests.

### qRT-PCR data

we exported cycle threshold (CT) values from sequence detection system (SDS) software into a Microsoft® Excel spreadsheet and compared the mean delta cycle threshold (dCT) values *vs.* the housekeeper gene (Student\'s *t*-test). From these values, we calculated and plotted the delta dCT (ddCT) and relative quantification of mRNA expression changes (2^∧^ddCT) values.

### Sequencing data

We analysed sequencing using Applied Biosystems SeqScape® software and aligned experimental sequences with known sequences derived from bioinformatic databases such as ENSEMBL genome browser (<http://www.ensembl.org/index.html>).

Results
=======

At 5 weeks (prior to any rise in blood pressure), there were more differentially expressed genes between SHRSP and WKY than at 16 or 21 weeks: 162 were differentially expressed in both brain regions, plus 202 just in frontal and 88 just in mid-coronal sections (total 452). There were far fewer differentially expressed genes at 16 weeks (71 genes in both regions, 30 in frontal only, 20 in mid-coronal only, total 121) or 21 weeks (63 genes in both regions, 131 in frontal only, 47 in mid-coronal only, total 241).

Ingenuity Pathway Analysis of all 452 differentially expressed genes at 5 weeks showed that these involved several functional pathways (Table [1](#tbl1){ref-type="table"}), many of which remained affected at 16 and 21 weeks (Table [2](#tbl2){ref-type="table"}). A common feature in both brain regions was the striking over-representation of genes for 'neurological disease' (Figure [1](#fig01){ref-type="fig"}) particularly those involved in *encephalopathy*, *stroke*, *depression* and *blood brain barrier leakage* (Table [3](#tbl3){ref-type="table"}; further details in Tables S1 and S2).

###### 

Summary of analysis of differential gene expression by functional group in frontal and mid-coronal sections of 5-week-old SHRSP and WKY rats performed using Ingenuity Pathway Analysis (see Table S1 for similar analysis in 16- and 21-week rats)

                                         Frontal   Mid-coronal               
  -------------------------------------- --------- -------------------- ---- --------------------
  Diseases and disorders                                                     
   Neurological disease                  79        1.51E-10--1.44E-02   48   3.80E-07--1.02E-02
   Genetic disorder                      84        1.92E-09--1.44E-02   41   6.19E-06--1.02E-02
   Skeletal and muscular disorders       72        1.92E-09--1.44E-02   50   6.19E-06--1.02E-02
   Connective tissue disorders           40        3.82E-06--1.44E-02   NA   NA
   Inflammatory disease                  48        3.82E-06--1.44E-02   NA   NA
   Developmental disorder                NA        NA                   34   1.12E-05--1.02E-02
   Organismal injury and abnormalities   NA        NA                   18   5.62E-05--8.69E-03
  Molecular and cellular functions                                           
   Gene expression                       70        7.55E-07--1.44E-02   54   2.83E-08--1.02E-02
   Cell death                            86        5.00E-06--1.44E-02   NA   NA
   Cell morphology                       60        2.14E-05--1.44E-02   NA   NA
   Carbohydrate metabolism               3         2.90E-05--1.44E-02   26   1.04E-06--1.02E-02
   Lipid metabolism                      21        2.90E-05--1.44E-02   54   5.18E-08--1.02E-02
   Small molecule biochemistry           NA        NA                   44   5.18E-08--1.02E-02
   Cellular growth and proliferation     NA        NA                   66   1.44E-06--1.02E-02

###### 

Summary of differential gene expression by functional group in frontal and mid-coronal sections of 16- and 21-week-old SHRSP and WKY rats, performed using Ingenuity Pathway Analysis (see Table [1](#tbl1){ref-type="table"} for similar analysis of differentially expressed genes at 5 weeks)

                                             Frontal   Mid-coronal               
  ------------------------------------------ --------- -------------------- ---- --------------------
  **16 weeks**                                                                   
  Diseases and disorders                                                         
   Inflammatory response                     4         7.68E-05--4.99E-02   6    7.68E-05--2.86E-02
   Neurological disease                      22        1.01E-03--4.61E-02   18   5.06E-05--3.91E-02
   Connective tissue disorders               12        1.77E-03--2.86E-02   NA   NA
   Inflammatory disease                      15        1.77E-03--4.99E-02   NA   NA
   Skeletal and muscular disorders           14        1.77E-03--2.86E-02   NA   NA
   Psychological disorders                   NA        NA                   8    5.06E-05--7.23E-03
   Infectious disease                        NA        NA                   7    1.38E-04--2.86E-02
   Cardiovascular disease                    NA        NA                   6    5.68E-04--1.89E-02
  Molecular and cellular functions                                               
   Amino acid metabolism                     6         7.68E-05--4.61E-02   4    7.68E-05--3.56E-02
   Drug metabolism                           4         7.68E-05--2.12E-02   4    7.68E-05--3.56E-02
   Molecular transport                       11        7.68E-05--4.95E-02   17   7.68E-05--4.26E-02
   Small molecule biochemistry               16        7.68E-05--4.95E-02   19   7.68E-05--4.61E-02
   Cell death                                22        3.10E-03--4.61E-02   NA   NA
   Nucleic acid metabolism                   NA        NA                   6    3.19E-04--4.61E-02
  **21 weeks**                                                                   
  Diseases and disorders                                                         
   Neurological disease                      39        5.83E-08--2.19E-02   31   2.49E-07--2.06E-02
   Skeletal and muscular disorders           40        6.18E-07--2.19E-02   29   2.49E-07--1.29E-02
   Hereditary disorder                       34        7.50E-06--2.19E-02   27   2.49E-07--1.50E-02
   Cardiovascular disease                    15        1.61E-04--2.19E-02   NA   NA
   Developmental disorder                    19        3.20E-04--2.19E-02   14   1.13E-04--2.06E-02
   Inflammatory response                     NA        NA                   10   1.01E-04--2.06E-02
  Molecular and cellular functions                                               
   Cell-to-cell signalling and interaction   28        5.52E-06--2.19E-02   NA   NA
   Cell cycle                                9         5.38E-05--1.68E-02   NA   NA
   Cellular assembly and organization        28        5.38E-05--2.19E-02   NA   NA
   Cellular function and maintenance         39        1.61E-04--2.12E-02   NA   NA
   Cell death                                45        3.40E-04--2.19E-02   NA   NA
   Amino acid metabolism                     NA        NA                   6    7.98E-06--2.06E-02
   Small molecule biochemistry               NA        NA                   21   7.98E-06--2.41E-02
   Cell signalling                           NA        NA                   11   5.79E-05--2.06E-02
   Molecular transport                       NA        NA                   22   5.79E-05--2.41E-02
   Vitamin and mineral metabolism            NA        NA                   13   5.79E-05--2.18E-02

NA, not applicable.

![Heat maps were generated using hierarchical clustering of all significantly differentially expressed Neurological Genes from individual biological replicates of 5-week-old SHRSP and WKY animals. The relative expression of each gene is represented by colour intensity, where red is up and green is down-regulated in (a) 79 genes from the frontal region and (b) 48 genes identified in the mid-coronal region.](nan0040-0855-f1){#fig01}

###### 

Details of some differentially expressed genes in the 'neurological disorders' functional pathway identified in IPA related to encephalopathy, major depression, stroke and blood brain barrier leakage. More details of neurological and inflammatory pathways affected are provided in Tables S1 and S2

  Functions annotation              *P*-value   Predicted activation state   Regulation *z*-score   Molecules
  --------------------------------- ----------- ---------------------------- ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Encephalopathy                    1.51E-10                                 −0.706                 ALB, BHLHE40, C20orf7, C3, C4B (includes others), CTGF, DUSP1, EGR1, EGR2, EGR4, FAM173A, FGF12, FGF13, FKBP8, FOS, FOXG1, GABRA5, GFAP, GOLPH3, GPR98, HLA-DMA, IER5, JUNB, KCNC2, MAL2, MAP1B, MAP4K1, MYO1B, MYT1L, NFIA, NFIB, NGFR, PDCL, PDE10A, PGRMC1, PLCB1, PLP1 (includes EG:18823), POLL, POLR2I, PTEN, PTGS2, S100B, SCN2A, SCN3A, SCOC, SERPINI1, SGK1, SLC1A3, SNAP25, SSR3, STK17B, VSNL1, ZNF440/ZNF808
  Major depression                  1.78E-03                                                        BTG2, C7orf23, GABRA5, GFAP, IGFBP2, PDE10A, PSIP1, SYMPK, TTR
  Stroke                            1.95E-03                                                        ALB, GABRA5, NGFR, PTGS2, S100B, SNAP25, VSNL1
  Leakage of blood--brain barrier   2.01E-03                                                        PTGS2, SERPINI1

Network analysis of the differential gene expression showed significant up-regulation in SHRSP of transcription factors (Figure [2](#fig02){ref-type="fig"}) including *Fos*, *JunB*, *Btg2* and early growth response genes (*Egr1*, *Egr2*, *Egr4*), genes central to cell signalling (*Pgs2* \[*Cox2*\], *Nfkbia*, *Pten*, *Sgk1*), and C3; others were down-regulated (e.g. insulin-like growth factors \[*Igf2*\], albumin \[*Alb*\], *Gfap* and *Mmp14*).

![A network from the 'neurological disorders' functional group, representing interactions between differentially expressed genes in SHRSP *vs*. WKY rats at 5 weeks of age, generated by Ingenuity Pathway Analysis software. Genes highlighted in red are down-regulated and in green are up-regulated in SHRSP compared with WKY. Solid lines indicate direct interactions. Dotted lines indicate indirect interactions. Details of affected genes are given in Tables S1 and S2.](nan0040-0855-f2){#fig02}

Across all ages, biological pathway analysis using IPA showed that the most significantly differentially expressed genes were in the acute phase response signalling pathway, but other pathways including circadian rhythm and complement were also affected (Figure [3](#fig03){ref-type="fig"}). In the acute phase pathway, complement factor 3 (C3) was up-regulated, while *Alb* and *transcription factor 4* were down-regulated. All three components of the complement pathway (classic, lectin and alternate) were affected (*C3* up-regulated, *C2* and *C4* down-regulated) (Figure [4](#fig04){ref-type="fig"}). The top five affected pathways also included genes associated with tight junction structure and signalling in 16- and 21-week-old SHRSP.

![Details of genes in the 'acute phase response' biological pathway identified in Ingenuity Pathway Analysis, which are differentially expressed in the frontal section of SHRSP *vs.* WKY rats at 5 weeks of age. Genes highlighted red are down-regulated and in green are up-regulated in SHRSP compared with WKY. Solid lines indicate direct interactions. Dotted lines indicate indirect interactions.](nan0040-0855-f3){#fig03}

![Details of genes in the 'complement' biological pathway identified in Ingenuity Pathway Analysis, which are differentially expressed in the frontal section of SHRSP *vs.* WKY rats at 5 weeks of age. Genes highlighted red are down-regulated and in green are up-regulated in SHRSP compared with WKY. Solid lines indicate direct interactions. Dotted lines indicate indirect interactions.](nan0040-0855-f4){#fig04}

Among the most highly *up-regulated genes* were (Table [4](#tbl4){ref-type="table"}): rat genome database (RGD) gene *1564649* related to urinary albumin secretion (up ∼48-fold); ribosomal protein S9 (*Rps9*) a translation regulator involved in cell proliferation (up ∼26-fold); and guanylate cyclase soluble subunit alpha-3 (*Gucy1a3*, up ∼20-fold), the intracellular nitric oxide (NO) vascular smooth muscle receptor. Among the most *down-regulated genes* were: *Alb* (down approximately threefold at all ages); arginine vasopressin (*Avp*, down fourfold at 5 weeks); guanine nucleotide-binding protein alpha inhibiting 1 (*Gnai1*, down threefold at 16 weeks); and *oxytocin* (down approximately threefold at 21 weeks).

###### 

The top 10 up- and down-regulated genes in SHRSP *vs.* WKY in each brain section and for each age group. All genes listed are significantly differentially expressed when a FDR of *P* \< 0.05 is applied

  Age            Frontal section   Mid-coronal section                                                                        
  -------------- ----------------- --------------------- ---------- -------------- -------------- ---------------- ---------- -------
   5             *RGD1564649*      ×48.1                 *Mrpl18*   ×27.7          *RGD1564649*   ×59.7            *Mrpl18*   ×29.1
  *Rps9*         ×26.4             *HCG 2004593*         ×16.4      *Rps9*         ×25.6          *HCG 2004593*    ×13.2      
  *Gucy1a3*      ×21.8             *RGD1565336*          ×5.3       *Gucy1a3*      ×23.0          *RGD1565336*     ×4.6       
  *Fam151b*      ×8.3              *Ttr*                 ×3.4       *Fam151B*      ×6.7           *Avp*            ×4.3       
  *RGD1311103*   ×4.9              *Gpr98*               ×3.3       *RGD1311103*   ×4.9           *LOC100125697*   ×3.5       
  *Arc*          ×4.4              *LOC100125697*        ×3.2       *Znf597*       ×4.2           *Gpr98*          ×3.2       
  *Znf597*       ×4.1              *Alb*                 ×3.1       *Rnf149*       ×4.1           *Pxmp4*          ×3.1       
  *Rnf149*       ×3.9              *Colq*                ×2.9       *Arc*          ×3.9           *Csnk2a1*        ×2.6       
  *Junb*         ×3.5              *Pxmp4*               ×2.8       *Dusp1*        ×3.1           *Vps13c*         ×2.6       
  *Znf317*       ×3.4              *HLA-C*               ×2.6       *Rps16*        ×3.0           *C20orf7*        ×2.5       
  16             *RGD1564649*      ×46.7                 *Mrpl18*   ×25.4          *RGD1564649*   ×54.5            *Mrpl18*   ×31.4
  *Rps9*         ×24.0             *HCG 2004593*         ×12.3      *Rps9*         ×27.2          *HCG 2004593*    ×12.9      
  *Gucy1a3*      ×19.8             *RGD1565336*          ×4.7       *Gucy1a3*      ×14.5          *RGD1565336*     ×5.4       
  *Fam151B*      ×8.8              *LOC100125697*        ×4.0       *Fam151b*      ×7.9           *Gpr8*           ×3.7       
  *RGD1311103*   ×5.4              *Pxmp4*               ×3.9       *RGD1311103*   ×6.6           *Alb*            ×3.7       
  *Znf597*       ×4.0              *Alb*                 ×3.7       *Znf597*       ×4.0           *LOC100125697*   ×3.6       
  *Rps16*        ×3.1              *Gpr98*               ×3.2       *Avp*          ×3.8           *Vps13c*         ×3.3       
  *RGD1566136*   ×2.8              *Gnai1*               ×3.0       *RGD1566136*   ×3.0           *Csnk2a1*        ×3.3       
  *HLA-C*        ×2.8              *C7orf23*             ×2.9       *Rsp16*        ×2.9           *Pxmp4*          ×3.1       
  *Adpgk*        ×2.7              *RGD1564078*          ×2.8       *HLA-C*        ×2.8           *C7orf23*        ×3.0       
  21             *RGD1564649*      ×46.9                 *Mrpl18*   ×30.7          *RGD1564649*   ×45.6            *Mrpl18*   ×25.9
  *Gucy1a3*      ×20.3             *HCG 2004593*         ×11.3      *Gucy1a3*      ×20.7          *HCG 2004593*    ×14.1      
  *RSP9*         ×18.8             *Ttr*                 ×7.4       *Rsp9*         ×18.9          *RGD1565336*     ×4.7       
  *Fam151b*      ×7.3              *RGD1565336*          ×3.9       *Fam151b*      ×7.3           *Gpr98*          ×4.3       
  *RGD1311103*   ×6.6              *Alb*                 ×3.8       *RGD1311103*   ×4.8           *Oxt*            ×3.4       
  *Znf597*       ×4.8              *Gpr98*               ×3.8       *Znf597*       ×4.5           *Alb*            ×3.3       
  *RGD1566136*   ×3.7              *Pxmp4*               ×3.6       *Ttr*          ×3.7           *Mobp*           ×3.2       
  *Rnf149*       ×3.4              *Opcml*               ×3.6       *Rnf149*       ×3.4           *LOC100125697*   ×3.1       
  *Rps16*        ×3.2              *Actb*                ×3.4       *Adpgk*        ×3.4           *Pxmp4*          ×3.0       
  *HLA-C*        ×2.8              *LOC100125697*        ×3.2       *HLA-C*        ×3.3           *Vps13c*         ×2.8       

RGD, rat genome database; *Rps9*, ribosomal protein S9; *Gucy1a3*, guanylate cyclase 1, soluble, alpha 3; *Fam151b*, family with sequence similarity 151, member B; *Arc*, activity-regulated cytoskeleton-associated protein; *Znf*, zinc finger protein; *Rnf149*, ring finger protein 149; *Junb*, jun B proto-oncogene; *Mrpl18*, mitochondrial ribosomal protein L18; *Hcg*, human chorionic gonadotrophin; *Avp*, arginine vasopressin; LOC, location; *Gpr*, G-protein coupled receptor; *Alb*, albumin; *Colq*, collagen-like tail subunit of asymmetric acetylcholinesterase; *Pxmp4*, peroxisomal membrane protein 4; *Csnk2a1*, casein kinase 2, alpha 1 polypeptide; *Vps13c*, vacuolar protein sorting 13 homologue C; *C20orf7*, chromosome 20 open reading frame 7; *Hla-c*, myosin heavy chain class 1 receptor C; *Adpgk*, ADP-dependent glucokinase; *C7orf23*, chromosome 7 open reading frame 23; *Gnai1*, guanine nucleotide-binding protein, alpha inhibiting 1; *Opcml*, opioid-binding protein/cell adhesion molecule-like; *Actb*, beta actin; *Oxt*, oxytocin; *Mobp*, myelin-associated oligodendrocyte basic protein.

Compared with previously observed protein immunoreactivity [@b15], we saw no differences in mRNA expression of claudin-5, collagen I or Iba-1. However, *Mmp14* mRNA was down-regulated in SHRSP at 5 weeks and matrix metalloproteinase 14 (MMP14) has been shown to have a key role in modulating vessel stability and vascular responses to tissue injury by interacting with vascular molecules [@b27]. Down-regulated *Mbp* mRNA expression (2.6-fold) at 21 weeks was consistent with previously observed reduced myelin basic protein (MBP) immunoreactivity at all ages [@b15]. No relevant immunohistochemistry antibody was available to test for differential protein expression of AVP or GUCY1a3, but the mRNA data were consistent with other results 20--22.

qRT-PCR (Table S3) confirmed the microarray data for: MMP14 (down fivefold at 5 weeks, *P* \< 0.01); GFAP (down twofold at 5 weeks, *P* = 0.01); and AVP (down fourfold at 5 weeks, *P* \< 0.001) (Figure [5](#fig05){ref-type="fig"}). qRT-PCR did not confirm the *Alb*, *Gucy1a3*, *Mbp* or *Gpr98* findings. The *Alb* difference may be a 'floor effect' where low mRNA expression, detectable by the greater dynamic range of the mRNA microarray, was undetectable by qRT-PCR. Despite consistent \>15-fold *Gucy1a3* mRNA up-regulation in SHRSP at all ages in both brain sections, qRT-PCR showed no significant differences. Microarray and qRT-PCR probes examine different gene segments which are separated by \>1000 nucleotides. Whole gene sequencing demonstrated a SNP in the 3′ untranslated region (UTR) of the *Gucy1a3* gene at position 4379 (WKY cytosine, SHRSP thymine). Discrepancies between mRNA microarray, qRT-PCR and immunohistochemistry could be further explained either by a true functional difference caused by microRNA binding to the 3′UTR region [@b28], or by post-translational modification [@b29]. Post-translational modification may be a result of over-exposure to a neurotransmitter or increased levels of reactive oxygen species [@b30] known to be present in the SHRSP [@b22].

![Validation of significant changes in gene expression of (a) GFAP, (b) MMP14 and (c) AVP in 5-week-old rats using qRT-PCR. Bars represent the difference in fold change between WKY and SHRSP. Error bars represent the standard error of the mean. Each bar represents *n* = 4 rats. \**P* \< 0.05. \*\**P* \< 0.01. \*\*\**P* \< 0.001. (a) GFAP mRNA expression was significantly reduced in the frontal section of SHRSP. (b) MMP14 mRNA expression was significantly reduced in the frontal section of SHRSP. (c) AVP mRNA expression was significantly reduced in the mid-coronal section of SHRSP.](nan0040-0855-f5){#fig05}

Discussion
==========

Differential gene expression between SHRSP and WKY has been demonstrated, the top 10 differentially expressed genes having fold changes \>2.5, and passing a FDR of *P* \< 0.05. These differences were most pronounced at 5 weeks and diminished with age. The fact that the greatest difference in gene expression was seen in the youngest prehypertensive age group supports the hypothesis that there are genetic factors unrelated to primary hypertension that underlie susceptibility to damage to the neurovascular unit, and that some of these genes have reduced expression with ageing. It is possible that some of these pathways are related to age-specific processes such as developmental growth, although further genome analysis is required to assess this.

We demonstrate multiple transcription regulation differences across several key functional and biological pathways around the neurovascular unit that explain some of the SHRSP\'s complex brain pathology. The major biological pathways affected were 'neurological' and 'inflammatory'. The most affected genes were generally conserved across all three ages examined. This constellation of differentially expressed genes may together increase vulnerability to microvascular damage and stroke. Possible mechanisms which may be involved, suggested by the data from this study and immunohistochemistry [@b15], include: impaired endothelial integrity (reduced claudin 5, MMP14) increasing the vascular endothelial permeability to plasma components which damage the arteriolar wall and subsequently the perivascular brain; reduced albumin facilitates fluid exudation into the vessel wall and brain interstitium through impaired plasma osmotic pressure [@b31]; microglial inflammatory responses are heightened, reducing NO bioavailability due to increased NO degradation from superoxide species 22,32--34; myelination (decreased MBP) is impaired and gliosis (increased GFAP) is increased, worsening brain damage; impaired vasoregulation (decreased *Avp* and *Gnai1*) and possibly reduced NO bioavailability (functional increase in NO receptor *Gucy1a3*) further increase vulnerability to ischaemia through impaired cerebral vasodilatation.

Up-regulated inflammatory pathway genes indicate a chronically challenged immune system from early life also shown by others [@b12] which may trigger or accentuate the vascular and perivascular damage observed in older SHRSP compared with control strains. Several of the genes showing significant differential expression between SHRSP and WKY were downstream transcriptional targets of cAMP response element-binding protein (CREB) particularly the transcription factors (Figure [6](#fig06){ref-type="fig"}). Genes regulated by CREB have been implicated in vascular remodelling in salt-induced hypertensive disease [@b35]. We found no difference in mRNA expression of *Creb1*, but differential phosphorylation of *Creb1*, initiated by NO [@b36] could be the source of increased transcription factor expression, and if shown in future experiments, would provide further evidence of a central role for altered intracellular NO signalling.

![Heat maps generated using hierarchical clustering of the median expression from 5-, 16- and 21-week SHRSP and WKY downstream transcriptional targets of cAMP response element-binding protein (*Creb*). The relative expression of each probe is represented by colour intensity, where red is up and green is down-regulated in (a) 17 genes from the frontal (F) region and (b) 18 genes identified in the mid-coronal (M) region. Genes are listed on the right hand side.](nan0040-0855-f6){#fig06}

Reduced *Avp* is consistent with reported abnormalities in STR-2 loci [@b19] and associated with time to first stroke in SHRSP [@b20], highlighting the importance of intact vasoregulation. Potential functional differences in *Gucy1a3* are consistent with observed increases in endothelin 1A receptors [@b34] and lower bioavailability of NO in SHRSP due to increased NO degradation from superoxide species [@b22],[@b32],[@b33]. *Gucy1a3* was also identified in a recent GWAS of blood pressure and cardiovascular disease risk in humans [@b37].

The tight junction pathway defects concur with data from older SHRSP [@b38]. The strikingly and consistently abnormal acute phase response pathways concur with reports of proteinuria and raised serum inflammatory proteins prior to hypertension [@b39], although salt supplementation confounded these studies [@b12]. Increased complement and other inflammatory gene expression parallels the consistent observation of perivascular inflammation seen pathologically in humans for over a century [@b4]. Ten-month-old stroke-free SHRSP had *elevated* MBP in one study of rats from the same colony [@b40] in contrast to the present work. The rats in both studies were fed on the same diet and kept in identical conditions, so the different findings cannot be attributed to salt loading as in some earlier studies. The rats studied by Brittain *et al*. [@b40] at 10 months were the minority of stroke-free survivors as about 70% of the Glasgow SHRSP colony have had stroke by 9 months and died. As our rats were sacrificed young, we have no way of knowing if they were in the 70% that have stroke by 9 months or not. Of note, we did find histological evidence of early arteriolar fibrinoid microvascular changes in one SHRSP used in the gene expression analysis (EL Bailey and C Smith, unpub. obs.) in contrast to Brittain *et al*.

Although in this study we had limited numbers of rats, we had control animals kept under identical conditions, carefully blinded all analyses, had immunohistochemistry from the same rats\' opposite hemispheres, and used multiple overlapping methods to check our findings.

We consider this SHRSP rat data to be valid animal model data to help focus translation research. In humans, stroke is a complex multifactorial disease, making a complex spontaneous disease model highly relevant. A large meta-analysis of stroke GWAS data by METASTROKE has emphasized the need for specific stroke subtyping and has strongly suggested that different pathogenic mechanisms underlie the different stroke subtypes [@b18]. The genetic architecture of most human cerebral small vessel stroke is unknown, hampered by imprecise stroke phenotyping and multiple accumulating ageing-related comorbidities. Brain microarray studies in elderly patients with dementia show multiple vessel wall, endothelial and brain parenchymal abnormalities including endothelial leakage [@b41] but precipitating factors and underlying susceptibility are difficult to unravel from end-stage disease. Human GWAS support the multifactorial nature of SVD [@b17]. Blood--brain barrier permeability is increased early in disease development in SHRSP [@b42], and is a key feature associated with human SVD in several primary studies [@b1]. Abnormal vasoregulation, long suspected in human SVD and associated with time to first stroke in SHRSP [@b19] could be the final factor that precipitates SVD brain lesions once the multifactorial milieu described above is established. Human data from the Leiden Longevity Study suggests that individuals who survive into late old age (equivalent to 10 months in SHRSP) are less susceptible to white matter damage and lacunar infarcts [@b43] and we would be interested to study older (10 months) stroke-free SHRSP rats to assess myelin integrity.

In summary, our data supports the multifactorial theory of SVD, with a number of genetic predispositions and biological pathways potentially contributing to the typical pathology. A similar targeted approach using new single cell mRNA technologies should be considered to determine if a similar pattern of low-level multifactorial defects in several components of the neurovascular unit might explain susceptibility to human SVD.
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 Details of differentially expressed genes in the 'neurological disorders' functional pathway identified in IPA.

Table S2. Details of differentially expressed genes in the 'inflammation' functional pathway identified in IPA.

Table S3. Genes from the microarray chosen for quantitative validation with qRT-PCR, the reasons and data obtained from qRT-PCR analysis. Numbers are the mean difference (± the standard error of the mean) in CT values between the gene of interest and the house keeper gene GAPDH for SHRSP and WKY at ages 5--21 weeks and from frontal (F) and mid-coronal (M) brain sections.
